Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia

Molecular Therapy

Volumn 19, Issue 7, 2011, Pages 1273-1286

  Ronen, Keshet ^a   Negre, Olivier ^b,c,d   Roth, Shannah ^a   Colomb, Charlotte ^b,c   Malani, Nirav ^a   Denaro, Maria ^d   Brady, Troy ^a   Fusil, Floriane ^b,c   Gillet Legrand, Beatrix ^b,c,d   Hehir, Kathleen ^d   Beuzard, Yves ^d   Leboulch, Philippe ^b,c,e   Down, Julian D ^d,f   Payen, Emmanuel ^b,c   Bushman, Frederic D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d BLUEBIRD BIO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; BUSULFAN; FLUOROURACIL; HEMOGLOBIN; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CLONE; CONTROLLED STUDY; ERYTHROCYTE COUNT; EX VIVO GENE TRANSFER; FEMALE; GROWTH REGULATION; HEMOGLOBIN BLOOD LEVEL; HMGA2 GENE; LONG TERMINAL REPEAT; MALE; MOUSE; NONHUMAN; PROTO ONCOGENE; RETICULOCYTE; SPLEEN WEIGHT; TRANSPOSON;

MURINAE; MUS;

EID: 79959935594     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.20     Document Type: Article

References (51)

1. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672. (Pubitemid 30241569)
2. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413. (Pubitemid 34734219)
3. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
4. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
5. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467: 318-322.
6. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
7. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
8. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
9. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696. (Pubitemid 43882120)
10. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
11. Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
12. Arumugam, PI, Higashimoto, T, Urbinati, F, Modlich, U, Nestheide, S, Xia, P et al. (2009). Genotoxic potential of lineage-specific lentivirus vectors carrying the ?-globin locus control region. Mol Ther 17: 1929-1937.
13. Wang, GP, Garrigue, A, Ciuffi, A, Ronen, K, Leipzig, J, Berry, C et al. (2008). DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 36: e49.
14. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751. (Pubitemid 36712571)
15. Cattoglio, C, Facchini, G, Sartori, D, Antonelli, A, Miccio, A, Cassani, B et al. (2007). Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110: 1770-1778. (Pubitemid 47443887)
16. Wang, GP, Berry, CC, Malani, N, Leboulch, P, Fischer, A, Hacein-Bey-Abina, S et al. (2010). Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood 115: 4356-4366.
17. Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529. (Pubitemid 35232295)
18. Wang, GP, Ciuffi, A, Leipzig, J, Berry, CC and Bushman, FD (2007). HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res 17: 1186-1194. (Pubitemid 47204862)
19. Levine, BL, Humeau, LM, Boyer, J, MacGregor, RR, Rebello, T, Lu, X et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377. (Pubitemid 44788976)
20. Wang, GP, Levine, BL, Binder, GK, Berry, CC, Malani, N, McGarrity, G et al. (2009). Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 17: 844-850.
21. Imren, S, Fabry, ME, Westerman, KA, Pawliuk, R, Tang, P, Rosten, PM et al. (2004). High-level ?-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest 114: 953-962. (Pubitemid 39578723)
22. Malik, P, Arumugam, PI, Yee, JK and Puthenveetil, G (2005). Successful correction of the human Cooley's anemia ?-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann N Y Acad Sci 1054: 238-249. (Pubitemid 43031030)
23. Puthenveetil, G, Scholes, J, Carbonell, D, Qureshi, N, Xia, P, Zeng, L et al. (2004). Successful correction of the human ?-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453. (Pubitemid 39564412)
24. Bank, A, Dorazio, R and Leboulch, P (2005). A phase I/II clinical trial of ?-globin gene therapy for ?-thalassemia. Ann N Y Acad Sci 1054: 308-316. (Pubitemid 43031038)
25. Nishino, J, Kim, I, Chada, K and Morrison, SJ (2008). Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 135: 227-239.
26. Cleynen, I and Van de Ven, WJ (2008). The HMGA proteins: a myriad of functions (Review). Int J Oncol 32: 289-305. (Pubitemid 351188295)
27. Gabriel, R, Eckenberg, R, Paruzynski, A, Bartholomae, CC, Nowrouzi, A, Arens, A et al. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 15: 1431-1436.
28. Berry, C, Hannenhalli, S, Leipzig, J and Bushman, FD (2006). Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2: e157.
29. Down, JD and Ploemacher, RE (1993). Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with γ radiation and cytotoxic drugs. Exp Hematol 21: 913-921. (Pubitemid 24215353)
30. Persons, DA, Allay, ER, Sabatino, DE, Kelly, P, Bodine, DM and Nienhuis, AW (2001). Functional requirements for phenotypic correction of murine ?-thalassemia: implications for human gene therapy. Blood 97: 3275-3282.
31. Roberts, C, Kean, L, Archer, D, Balkan, C and Hsu, LL (2005). Murine and math models for the level of stable mixed chimerism to cure ?-thalassemia by nonmyeloablative bone marrow transplantation. Ann N Y Acad Sci 1054: 423-428. (Pubitemid 43031050)
32. Kean, LS, Manci, EA, Perry, J, Balkan, C, Coley, S, Holtzclaw, D et al. (2003). Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood 102: 4582-4593. (Pubitemid 37494128)
33. Li, CK, Chik, KW, Tsang, KS, Pong, H, Shing, MM and Yuen, PM (2002). Mixed chimerism after bone marrow transplantation for thalassemia major. Haematologica 87: 781-782. (Pubitemid 34787155)
34. Lisini, D, Zecca, M, Giorgiani, G, Montagna, D, Cristantielli, R, Labirio, M et al. (2008). Donor/recipient mixed chimerism does not predict graft failure in children with ?-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica 93: 1859-1867.
35. Kustikova, OS, Schiedlmeier, B, Brugman, MH, Stahlhut, M, Bartels, S, Li, Z et al. (2009). Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17: 1537-1547.
36. Miller, DG, Petek, LM and Russell, DW (2004). Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 36: 767-773. (Pubitemid 38886641)
37. Selten, G, Cuypers, HT and Berns, A (1985). Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J 4: 1793-1798.
38. Dabrowska, MJ, Dybkaer, K, Johnsen, HE, Wang, B, Wabl, M and Pedersen, FS (2009). Loss of MicroRNA targets in the 3' untranslated region as a mechanism of retroviral insertional activation of growth factor independence 1. J Virol 83: 8051-8061.
39. Dickson, C, Smith, R, Brookes, S and Peters, G (1990). Proviral insertions within the int-2 gene can generate multiple anomalous transcripts but leave the protein-coding domain intact. J Virol 64: 784-793. (Pubitemid 20032695)
40. Corcoran, LM, Adams, JM, Dunn, AR and Cory, S (1984). Murine T lymphomas in which the cellular myc oncogene has been activated by retroviral insertion. Cell 37: 113-122. (Pubitemid 14079842)
41. Sorrentino, B (2010). Assessing the risk of T-cell malignancies in mouse models of SCID-X1. Mol Ther 18: 868-870.
42. Mantovani, J, Charrier, S, Eckenberg, R, Saurin, W, Danos, O, Perea, J et al. (2009). Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J Gene Med 11: 645-654.
43. Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240. (Pubitemid 47219568)
44. Meekings, KN, Leipzig, J, Bushman, FD, Taylor, GP and Bangham, CR (2008). HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog 4: e1000027.
45. Smit, AF (1999). Interspersed repeats and other momentos of transposable elements in mammalian genomes. Curr Opin Genet Dev 9: 657-663.
46. Brady, T, Lee, YN, Ronen, K, Malani, N, Berry, CC, Bieniasz, PD et al. (2009). Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev 23: 633-642.
47. Maruggi, G, Porcellini, S, Facchini, G, Perna, SK, Cattoglio, C, Sartori, D et al. (2009). Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther 17: 851-856.
48. Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C et al. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in ?-thalassemic hematopoietic cells. Mol Ther 16: 525-533. (Pubitemid 351314992)
49. Imren, S, Payen, E, Westerman, KA, Pawliuk, R, Fabry, ME, Eaves, CJ et al. (2002). Permanent and panerythroid correction of murine thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 99: 14380-14385. (Pubitemid 35257680)
50. Pawliuk, R, Westerman, KA, Fabry, ME, Payen, E, Tighe, R, Bouhassira, EE et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371. (Pubitemid 33140563)
51. Brady, T, Roth, SL, Malani, N, Wang, GP, Berry, CC, Leboulch, P et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res, in press.